ArticleDigestive diseases and sciences2026
CASC15 Promotes Cholangiocyte Proliferation and Liver Fibrosis by Regulating the HNRNPU-IGFBP3 Axis in Biliary Atresia.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeActive cholangiocytes featured with massive proliferation activate hepatic stellate cells (HSCs) and could cause eventual liver fibrosis (LF), however, this crosstalk still remains unclear in biliary atresia (BA). We aimed to evaluate the involvement of cancer susceptibility candidate 15 (CASC15) in BA.
methodsCholangiocyte organoid culture and sequencing was used to identify differentially expressed long noncoding RNA associated with cholangiocyte proliferation. The expression level of CASC15 were detected in liver tissues. The CCK-8, EdU assay, co-culture experiments, and subcellular fractionation were employed to investigate its function and subcellular localization. Chromatin isolation by RNA purification coupled with mass spectrometry, RNA immunoprecipitation, and RNA sequencing were utilized to clarify the underlying mechanism of CASC15.
resultsCASC15 showed increased expression in cholangiocyte organoids and liver tissues of BA patients. Overexpressed CASC15 in cholangiocytes enhanced cell proliferation and promoted HSC activation in vitro. CASC15 predominantly located in the nucleus and was identified to interact with heterogeneous nuclear ribonucleoprotein U (HNRNPU) to maintain the expression of downstream target insulin-like growth factor binding protein 3 (IGFBP3), which could facilitate in the activation of HSCs.
conclusionThis research revealed the crucial role of CASC15/HNRNPU-IGFBP3 regulatory network in the pathogenesis of LF in BA.
Indexed as
Identifiers
41688795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.